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Objective. The Arkansas Prescription Monitoring Program (AR PMP) was implemented in 2013 to combat
prescription drug abuse. All enrollees were invited to participate in a user survey available in February 2014, to
identify makeup of users, utilization of the program, and changes made to health care practices after implemen-
tation of the program.
Methods. Of the 3694 individual enrollees invited to participate, 1541 (41.7%) completed the survey. Data
collected were analyzed to identify changes in health care practices by program frequency of use and user
profession.Results.Medical doctors, advanced practice nurses, and pharmacists are the professions who use the program
most frequently. Daily AR PMPusers are considerablymore likely than infrequent users to be prompted to access
the program by the involvement of a controlled substance (CS) prescription or by ofﬁce/facility policy require-
ments. Increased frequency of use of the AR PMP results in positive impacts on CS prescribing and dispensing
practices.
Conclusion. Compelling more users of the AR PMP to be prompted to access the program by the involvement
of a CSprescription or by requirements per ofﬁce/facility policymay increase frequency of use of the programand
thereby changes in health care practices to combat prescription drug abuse.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prescription drug abuse is deﬁned as using prescription drugs for
nonmedical/nonprescribed purposes, such as intoxication or mood
alteration. This illegal and dangerous health behavior has increased
over the past two decades. Overdose deaths due to prescription pain-
killers quadrupled from 1999 to 2010, going from 4030 to 16,651, and
were more prevalent than overdose deaths from heroin and cocaine
combined in 2010 (National Vital Statistics System, 2012). As of 2010,
60% of all drug overdose deaths were from prescription drugs, with
opioids being involved in 3 of every 4 of these deaths. Prescription
drug abuse in the United States is now described by the Centers for
Disease Control and Prevention (CDC) as an epidemic (National Vital
Statistics System, 2012). The signiﬁcant increase in prescription drugt, #781, Little Rock, AR 72205-
Rittenhouse), FWei@uams.edu
RyanKevinW@uams.edu
. This is an open access article underabuse can largely be attributed to the increased availability of prescrip-
tion drugs. Although these prescription medications are prescribed for
legitimate medical purposes, a portion of them become subject to
drug diversion for recreational, non-medicinal use. Increased prescrib-
ing and the availability of these drugs are directly correlated to
increased overdose deaths (Vital Signs, 2011). This paper describes an
intervention to address this critical public health issue.
The CDC's Injury Center has made combating prescription drug
abuse a principal focus of its strategic plan. Among other proposed
interventions, they recommend the implementation of state run
Prescription Drug Monitoring Programs (PDMP) to help mitigate this
public health epidemic (Vital Signs, 2011). Through utilization of
electronic databases, these programs allow enrollees the ability to
track where and when patients are acquiring controlled substance
(CS)medications, thereby assisting health care professionals in identify-
ing drug seeking patients who may be abusing prescription drugs.
PDMPs have the potential to drastically decrease the amount of drug
diversion in the United States, which in turn can directly affect the
rates of prescription drug abuse and overdose.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Arkansas PrescriptionMonitoring Program2014User Survey respondentswho completed
the survey.
n Percentage Actual
percentagea
Profession (n = 1541)
Medical doctor 536 34.8 37.0
Advanced practice nurse 210 13.6 12.2
Pharmacist 631 41.0 39.9
Other 164 10.6 10.9
Region (n = 1541)
Central 546 35.4
Medical doctor 220 40.3
Advanced practice nurse 64 11.7
Pharmacist 208 38.1
Other 54 9.9
Northeast 321 20.8
Medical doctor 92 28.7
Advanced practice nurse 57 17.8
Pharmacist 130 40.5
Other 42 13.1
Northwest 446 28.9
Medical doctor 153 34.3
Advanced practice nurse 53 11.9
Pharmacist 186 41.7
Other 54 12.1
Southeast 107 6.9
Medical doctor 32 29.9
Advanced practice nurse 20 18.7
Pharmacist 47 43.9
Other 8 7.5
Southwest 121 7.9
Medical doctor 39 32.2
Advanced practice nurse 16 13.2
Pharmacist 60 49.6
Other 6 5.0
Frequency of access (n = 1541)
Daily 325 21.1
2-3 times weekly 353 22.9
At least once a week 394 25.6
Less than 3 times a month 403 26.2
Never 66 4.3
Timing of access (n = 1475)b
Before issuing/dispensing a CS rxc 1187 80.5
After issuing/dispensing a CS rx 65 4.4
During patient consultation 159 10.8
Not applicable 64 4.3
Reasons for access (all that apply) (n =
1475)b
Any time involving a CS rx 348 23.6
Any time involving a C-II CS rx 220 14.9
Any suspicion of misuse/drug diversion 1342 91.0
Requests from other
prescribers/pharmacists
414 28.1
Required per ofﬁce/facility policy 163 11.1
Not Applicable 10 0.7
a The actual overall AR PMP user composition, calculated in March 2014 by the ADH.
b 66 participants who answered “Never” to the frequency of access question were
excluded.
c CS: controlled substance, rx: medical prescription.
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304 of 2011 and implemented in 2013 as the Arkansas Prescription
Monitoring Program (AR PMP) (Arkansas Department of Health,
2013). The program is administered by the Arkansas Department
of Health (ADH) with the following goals:
• To enhance patient care by providing prescription monitoring
information that will ensure legitimate use of controlled substances
in health care;
• To help curtail the misuse and abuse of controlled substances;
• To assist in combating illegal trade in and diversion of controlled
substances;
• To enable access to prescription information by practitioners, law
enforcement agents and other authorized individuals and agencies
(Arkansas Department of Health, 2013).
The AR PMP collects, stores, and monitors the dispensing of CS in
Schedules II, III, IV, and V, as well as other state-controlled drugs
(Arkansas Department of Health, 2013). Dispensers report patient
name, address and date of birth, physician identiﬁcation, pharmacy
identiﬁcation, prescription number, drug name, strength, quantity
and date prescribed. Collection of this data began on March 1, 2013
and must be reported by prescription drug dispensers to the ADH
on a weekly basis. Through authorized access to the AR PMP data-
base, practitioners may view the CS dispensing history of their pa-
tients, including the exact quantity of medication prescribed by
each prescriber and dispensed at each pharmacy, in order to make
more informed prescribing and dispensing decisions.
Our objective in this study was to better understand the utiliza-
tion and performance of the AR PMP during the ﬁrst year of its im-
plementation. Speciﬁcally, we sought to describe (1) the makeup
of AR PMP users; (2) the utilization of the AR PMP; and (3) the per-
formance of the program in regard to changing prescribing and dis-
pensing practices. The results of the study survey were used to
evaluate how access to the AR PMP is changing health care practices
in efforts to address the public health epidemic of prescription drug
abuse.
Methods
Procedure
A web survey was developed and administered via SurveyMonkey
(online web based survey tool). All enrolled Arkansas prescribers and
dispensers (n = 3694) were invited by email to participate in the
study survey, which was available for 30 days from February 4 to
March 5, 2014. Two reminder emails with the survey link invitation
were sent out on days 14 and 28. The survey was designed with seven
questions to take no more than 2 min to complete at the individual's
convenience over the course of 30 days. The survey was anonymous
and e-mail addresses were deleted at the end of the survey period.
The ADH reviewed and determined that the survey project did not
require human subject review.
Measures
Survey questions were designed by investigators of the study
after review of other states' PDMP surveys and upon solicitation of
AR PMP staff suggestions and statistical expert opinions. All survey
questions were closed-ended (Appendix A). The AR PMP User Sur-
vey was created with three objectives. The ﬁrst study objective, to
describe the makeup of AR PMP users, was addressed by the follow-
ing: “Which of the following best describes your profession?” and
“Where is your primary practice located?” The second study objec-
tive, to identify the utilization of the AR PMP, was answered by thefollowing: “How often do you use the AR PMP?”, “When do you use
the AR PMP?” and “What prompts you to access the AR PMP?” The
last study objective, to identify how the AR PMP has changed pre-
scribing and dispensing practices, was answered by the last two sur-
vey questions in order to determine the performance of the program
over the past year. One question was more patient speciﬁc: “After
reviewing the AR PMP, how has a patient encounter been altered?”
and the other more practice speciﬁc: “How has access to the AR
PMP changed your prescribing/dispensing practices?” All statistical
data analyses for this study were generated using SAS® software,
Version 9.3 of the SAS System for Windows.
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User makeup and program utilization
The makeup of the AR PMP User Survey participants is outlined in
Table 1, closely resembling the actual AR PMP user composition that
was calculated in March 2014 by the ADH (Arkansas Department of
Health, 2013). There were a total of 1541 individuals who completed
the survey, giving an overall response rate of 41.7%. Survey respondents
were from health care practices located in all 75 Arkansas counties. The
utilization of the AR PMP is described in terms of frequency of access,
timing of access, and reasons for access of the AR PMP, as outlined in
Table 1.
Very few (4%) AR PMP enrollees reported never accessing the pro-
gram. Of those who access the AR PMP daily, 43% are PharmD/PDs,
36% are MDs, and 14% are APNs. Similar to the frequency of access
distribution of all AR PMP users as outlined in Table 1, the frequency
of use by MDs, APNs and PharmD/PDs is equally distributed in terms
of how often they access the program.
Among the daily and infrequent users (those who use the program
less than three times a month), the most common reasons to access
the program are similar: suspicion of drug misuse or drug diversion
(92% of infrequent users and 84% of daily users, Chi-square statistical
test p-value= 0.0024) and requests from other prescribers or pharma-
cists (29% of infrequent users and 28% of daily users, p-value= 0.8156).
However, daily users are considerablymore likely than infrequent users
to be prompted to access the program simply due to any involvement
of a CS prescription (49% v. 8%, p-value b 0.0001), any involvement of
a C-II CS prescription (32% v. 5%, p-value b 0.0001) or requirements
per ofﬁce or facility policy (22% v. 4%, p-value b 0.0001). Fig. 1 shows
the reasons that AR PMP users are prompted to access the program
among the professions with the most frequent use of the program.
Changes in health care practices
Among the 1475 study participants who access the AR PMP, the
most common response as to how access to the program has impacted
their health care practices was by causing a decrease in the number of32%
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Fig. 1. Reasons for access to the Arkansas PrescriptionMonitoring Program by the Professio
choose all reasons that apply to them, 31 medical doctors, 7 advanced practice nurses and 22 p
controlled substance, rx: medical prescription. bp-Value b 0.0001was the Chi-square test result
who accessed to the Arkansas Prescription Monitoring Program because of anytime a prescripCS prescriptions issued or dispensed (61%), closely followed by causing
them to provide more patient education and/or counseling on CS
prescription use and abuse (57%). Access to the AR PMP is also causing
users to decrease the quantity of dosage units prescribed (24%) and to
increase the number of prescriptions changed from a C-II to a C-III/C-
IV (7%). An insigniﬁcant number of survey respondents (0.8%) reported
an increased number of CS prescriptions issued or dispensed after
access to the AR PMP.
Compared to infrequent users who utilize the program less than
three times a month, those who access the program daily were almost
twice as likely to report that the program has caused them to decrease
the number of CS prescriptions issued or dispensed (76% v. 39%, p-
value b 0.0001). Daily users were 23% more likely to report that the
AR PMP has caused them to provide more patient education and/or
counseling on CS prescription use and abuse (67% v. 44%, p-
value b 0.0001), they were twice as likely to report the AR PMP has
caused them to decrease the quantity of dosage units prescribed for
CS prescriptions (30% v. 15%, p-value b 0.0001) and they were almost
three times as likely to report the AR PMP has caused an increase in
prescriptions changed from a C-II to a C-III/C-IV (11% v. 4%, p-value =
0.0006) after accessing the AR PMP.
Reported changes to health care practice after accessing the AR PMP
by the professionswith themost frequent use of the programare shown
in Fig. 2.
Discussion
The epidemic of prescription drug abuse has resulted in calls for new
measures to address this devastating, life threatening public health
issue. The AR PMP, as authorized by Arkansas Act 304 of 2011, has
already changed health care practices across the state during its ﬁrst
year of operation. The results of this study show that the makeup of
AR PMP users can be described as prescribing and dispensing health
care professionals representing all 75 Arkansas counties. Program utili-
zation analysis showed a large portion of AR PMP users regularly access
the programeither two to three timesweekly or daily, with themajority
of users accessing before issuing or dispensing a CS prescription, poten-
tially preventing CSmedications frombeing obtained by drug seekers or5%
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b
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Fig. 2. Changes in Health Care Practices after Accessing the Arkansas PrescriptionMonitoring Program by the Professions with theMost Frequent Use of the Program, 2014a,b. aIn
the survey, respondents could choose all reasons that apply to them; 31medical doctors, 7 advanced practice nurses and 22 pharmacistswho answered “Never” to the frequency of access
questionwere excluded, CS: controlled substance, rx: medical prescription. bSince a PharmD/PD cannot prescribemedications in Arkansas, the prescriberwould have had to be contacted,
therefore prompting a prescription change.
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to the AR PMP relates to changes in health care practices. A majority
of AR PMP users responded that the program had caused them to de-
crease the number of CS prescriptions issued or dispensed and to
provide more patient education and/or counseling on CS medication
use and abuse. Program use also resulted in decreases in the dosage
unit quantity of CS medication issued or dispensed and increases in
the number of prescriptions changed from a C-II to a C-III/C-IV med-
ication. These are positive actions in achieving the goals set out by
the AR PMP. During the ﬁrst year of implementation, the program
demonstrated potential to mitigate misuse and abuse of CS medica-
tions. Through access to the AR PMP, health care professionals are
better able to ensure the legitimate use of CS prescriptions and to
take necessary measures when diversion is suspected.
This study demonstrated several limitations beginning with the
low response rate of 41.7%. This response rate is likely attributable
to several factors; email ﬁlter blocking of SurveyMonkey emails,
the decision not to include partially completed surveys (3% of re-
spondents) in the analyses, and the relatively short window for re-
sponse (30 days).
Additionally it is possible that non-respondents were not able to ac-
cess the AR PMP as often as respondents resulting in a possible overes-
timate of AR PMP utilization rates.
While the seven question survey instrument was intentionally brief
in order to encourage participation from busy health care professionals,
a longer survey could provide more reﬁned information regarding AR
PMP users and its impact on their prescribing practices.
Questions 4 through 7 of the survey allowed participants to choose
the response N/A. This response optionmay have been selected for sev-
eral reasons, including that they never use the program, they found
none of the responses satisfactory, or they had additional responses
they wished to express. This option resulted in a level of impreciseness
in the study results.
Also, it is possible that changes in health care practices related to CS
prescribing and dispensing could also be attributed to unknown forcesoperating concurrently to the operation of the AR PMP, confounding
the results of this study.
Finally, the results of this study came from a PDMP operating in
Arkansas, a largely rural state. Extrapolating from these results to
more urbanized states should be undertaken with care.
Conclusion
It appears clear that the AR PMP has positively impacted pre-
scription drug abuse in our state. Increased frequency of access by
health care providers to the PDMP appears essential to improving
their CS practices. Daily users are signiﬁcantly more likely than in-
frequent users to be prompted to access the AR PMP simply by the
involvement of a CS prescription or by requirements per ofﬁce or fa-
cility policy. Currently, neither Arkansas law nor regulation man-
dates that CS prescribers and dispensers access the AR PMP. It is
likely that legal and regulatory requirements will result in increased
PDMP utilization. Additionally, increased utilization of the AR PMP
database is likely to occur as a result of planned program enhance-
ments such as unsolicited reporting (providing alerts to registered
and non-registered users of the appearance of misuse or abuse by
a patient) and allowing prescribers/dispensers to designate dele-
gates to access the database. These actions along with continued
support of stakeholders in the adoption of CS prescribing and dis-
pensing guidelines by healthcare facilities remain key strategies in
combating prescription drug abuse.
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Appendix A. Arkansas Prescription Monitoring Program 2014 User
Survey
Supplementary data to this article can be found online at http://dx.
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